Alterity Therapeutics Raises A$20.0 million in Strategic Placement
MELBOURNE, Australia and SAN FRANCISCO, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”),...
Day: September 8, 2025
ElevateBio Appoints Larry Lockwood, Ph.D., as Chief Commercial Officer
Dr. Lockwood brings more than 20 years of experience driving revenue growth and establishing global partnerships for manufacturing and research...
TG Announces Phase 3 Trial for Subcutaneous BRIUMVI Commenced Enrollment
Phase 3 trial to evaluate two subcutaneous BRIUMVI dosing regimensNEW YORK, Sept. 08, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc....
Angitia Biopharmaceuticals Presents First-in-Human Data on AGA2115 for Osteogenesis Imperfecta at ASBMR 2025
• Clinical data demonstrated administration of AGA2115 drove dose-dependent increases in bone mineral density • The Company and collaborators also...
Insight Molecular Diagnostics Announces Positive Strategic Update and Novel Registry Database
5,000-participant, multi-center registry supported by iMDx’s central lab and transplant center partnersNew hospital-based data seeks to further differentiate pending kitted...
Kraig Biocraft Laboratories Appoints Kenneth Le as Managing Director of Prodigy Silk
ANN ARBOR, Mich., Sept. 08, 2025 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("Company" or "Kraig Labs"), a...
Pasithea Therapeutics Announces Enrollment of Cohort 2 following Positive Safety Review Committee (SRC) Recommendation for its Ongoing Phase 1/1b Clinical Trial of PAS-004 in Adult NF1 Patients
-- Recommendation that trial escalate to next dose level of 8mg tablet -- -- Initial interim clinical data from first two...
Picard Medical, Inc. Announces Presentation at H.C. Wainwright Global Investment Conference
TUCSON, Ariz., Sept. 08, 2025 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE American: PMI) (“Picard” or the “Company”), today announced...
EDAP Receives HIFU Reimbursement for Prostate Cancer in France
Focal One Robotic HIFU procedure now covered under France’s national universal health systemReimbursement milestone allows increased patient access to Focal One...
IMDX Enrolls First Patient in GraftAssureDx Clinical Trial and Welcomes New Hospital Participants
iMDx’s ClinicalTrials.gov listing now names 10 leading transplant centers, up from 5 previouslyGraftAssureDx remains on track for FDA submission by...
Attralus Presents New Data on Its Pan-Amyloid Diagnostic Imaging Candidates at ASNC 2025
124I-evuzamitide, the first pan-amyloid diagnostic imaging agent, demonstrated 100% sensitivity and specificity for the diagnosis of cardiac amyloidosis in patients...
Tonix Pharmaceuticals Presents Clinical Data on Tonmya™ for the Treatment of Fibromyalgia at PAINWEEK 2025
Tonmya was approved by FDA on August 15, 2025 for the treatment of fibromyalgia and is the first new FDA...
Ocular Therapeutix™ to Host Investor Day on September 30, 2025
Company to highlight ongoing AXPAXLI™ wet AMD registrational program, strategy and next steps in NPDR and DME, and global commercial...
Dianthus Therapeutics Announces Positive Data for Claseprubart (DNTH103) from the Phase 2 MaGic Trial in Generalized Myasthenia Gravis, Supporting Its Potential Best-In-Class Profile
Claseprubart 300mg and 600mg Q2W doses both achieved statistically significant and clinically meaningful improvements in Myasthenia Gravis Activities of Daily...
Regeneron Advances Allergy Pipeline with Two Positive Phase 3 Trials Evaluating First-in-Class Antibody-Blockers of Cat and Birch Allergies
In separate cat and birch allergen-challenge trials, single doses of allergen-specific antibody blockers significantly reduced allergy symptoms compared to placebo...
Serina Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference
HUNTSVILLE, AL, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing...
Rapport Announces Positive Topline Results from Phase 2a Clinical Trial of RAP-219 in Patients with Focal Onset Seizures
Trial met primary long episode endpoints with high statistical significance, and RAP-219 was generally well toleratedPatients achieved 77.8% reduction in...
Leading Austrian Pathology Laboratory Group Chooses PathAI’s AISight® Dx to Accelerate Digital Pathology and Advanced Diagnostics
Partnership includes use of PathAI’s CE-IVDR-marked AISight® Dx1 digital pathology image management system at a group of Austrian pathology laboratoriesBOSTON...
NRG Therapeutics Announces Oversubscribed £50m ($67m) Series B Financing to Deliver Clinical Data in Parkinson’s and Proof of Concept in ALS/MND
Oversubscribed £50m Series B led by SV Health Investors’ Dementia Discovery Fund, alongside other new investors British Business Bank, M...
ONWARD Medical Receives CE Mark for ARC-EX, Enabling Commercial Launch of Breakthrough Spinal Cord Stimulation System in Europe
THIS PRESS RELEASE CONTAINS INSIDE INFORMATION WITHIN THE MEANING OF ARTICLE 7(1) OF THE EUROPEAN MARKET ABUSE REGULATION (596/2014) The...